US Pharma MarketingLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments. Cancer FDA ASCO Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home Katherine MacPhail is a reporter and editorial events programmer for STAT. CHICAGO — What if the trick to getting cancer immunotherapy to parts of…
CHICAGO — What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose?
A lower-cost immunotherapy approach could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to results presented Sunday at the annual meeting of the American Society of Clinical Oncology.
Source: STAT News Pharma